Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ph-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer Publisher Pubmed



Moammeri A1 ; Abbaspour K1 ; Zafarian A2 ; Jamshidifar E3 ; Motasadizadeh H3, 4 ; Dabbagh Moghaddam F5 ; Salehi Z1 ; Makvandi P6 ; Dinarvand R3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, 111554563, Iran
  2. 2. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran
  3. 3. Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 141556451, Iran
  4. 4. Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1316943551, Iran
  5. 5. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, 1477893855, Iran
  6. 6. Istituto Italiano di Tecnologia, Center for Materials Interfaces, Pisa, 56025, Italy

Source: ACS Applied Bio Materials Published:2022


Abstract

Combination chemotherapy has become a treatment modality for breast cancer. However, serious side effects and high cytotoxicity associated with this combination therapy make it a high-risk method for breast cancer treatment. This study evaluated the anticancer effect of decorated niosomal nanocarriers loaded with cisplatin (CIS) and epirubicin (EPI) in vitro (on SKBR3 and 4T1 breast cancer cells) and in vivo on BALB/c mice. For this purpose, polyethylene glycol (PEG) and folic acid (FA) were employed to prepare a functionalized niosomal system to improve endocytosis. FA-PEGylated niosomes exhibited desired encapsulation efficiencies of ∼91.2 and 71.9% for CIS and EPI, respectively. Moreover, cellular assays disclosed that a CIS and EPI-loaded niosome (NCE) and FA-PEGylated niosomal CIS and EPI (FPNCE) enhanced the apoptosis rate and cell migration in SKBR3 and 4T1 cells compared to CIS, EPI, and their combination (CIS+EPI). For FPNCE and NCE groups, the expression levels of Bax, Caspase3, Caspase9, and Mfn1 genes increased, whereas the expression of Bcl2, Drp1, MMP-2, and MMP-9 genes was downregulated. Histopathology results showed a reduction in the mitosis index, invasion, and pleomorphism in BALB/c inbred mice with NCE and FPNCE treatment. In this paper, for the first time, we report a niosomal nanocarrier functionalized with PEG and FA for codelivery of CIS and EPI to treat breast cancer. The results demonstrated that the codelivery of CIS and EPI through FA-PEGylated niosomes holds great potential for breast cancer treatment. © 2022 The Authors. Published by American Chemical Society
Other Related Docs
14. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)
15. Plga-Peg-Ra-Based Polymeric Micelles for Tumor Targeted Delivery of Irinotecan, Pharmaceutical Development and Technology (2018)
16. Recent Progress in Cancer Immunotherapy: Application of Nano-Therapeutic Systems, Journal of Drug Delivery Science and Technology (2024)
25. Arsenic Polyoxotungstate-Zeolitic Imidazolate Framework-8 As a Potential Selective Anti-Cancer Nano Platform, Journal of Inorganic and Organometallic Polymers and Materials (2023)
35. Microrna: A Novel Target of Curcumin in Cancer Therapy, Journal of Cellular Physiology (2018)